Trial Profile

A Phase 1/2a 2-part Study Consisting of an Open-label Multiple Ascending Dose (MAD) Safety Study in Participants With Macular Edema Following Branch Retinal Vein Occlusion (BRVO), and a Dose-finding, Double-masked, Comparative Safety, and Preliminary Efficacy Study of Intravitreal (IVT) EYE201 (Tiespectus) in Participants With Either Diabetic Macular Edema (DME) or Neovascular Age-related Macular Degeneration (NVAMD)

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 24 Mar 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs EYE 201 (Primary)
Indications Age-related macular degeneration; Branch retinal vein occlusion; Diabetic macular oedema; Retinal oedema; Wet age-related macular degeneration
Focus Adverse reactions
Sponsors Merck & Co

18 Mar 2026 Planned End Date changed from 1 May 2026 to 31 May 2026.
18 Mar 2026 Planned primary completion date changed from 1 Apr 2026 to 30 Apr 2026.
18 Mar 2026 Status changed from recruiting to active, no longer recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com